This area is reserved for registered users. Please register or login.

Gabapentin – Respiratory Depression without Concomitant Opioid Use

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) concluded a review in 2017 of respiratory depression associated with gabapentin use without concomitant opioid therapy.   Gabapentin-containing medicinal products are licensed in Ireland under various brand names for the treatment of specific forms of epilepsy and also for the treatment of peripheral neuropathic pain. The risk of central nervous system (CNS) depression such as somnolence, sedation and respiratory depression in association with concomitant use of gabapentin and opioids is already known and is detailed in the Summary of Product Characteristics (SmPC) for gabapentin-containing medicinal products, where the…